The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LEGN | -36.2% | -11.86% | -2.49% | -27% |
| S&P | +12.93% | +85.68% | +13.18% | +113% |
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
Legend's cell therapy seems like it's a winner, but it might be priced in already.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $272.69M | 70.2% |
| Gross Profit | $151.12M | 52.2% |
| Gross Margin | 55.42% | -6.5% |
| Market Cap | $6.02B | -32.6% |
| Market Cap / Employee | $2.31M | 0.0% |
| Employees | 2.6K | 42.9% |
| Net Income | -$39.74M | 68.3% |
| EBITDA | -$37.39M | 42.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $278.96M | -39.3% |
| Accounts Receivable | $1.24M | 75.3% |
| Inventory | 29.2 | 23.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $259.99M | -24.0% |
| Short Term Debt | $150.25M | 3360.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.94% | 5.5% |
| Return On Invested Capital | -35.84% | -25.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $15.22M | 116.4% |
| Operating Free Cash Flow | $28.91M | 138.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.35 | 5.99 | 6.42 | 5.81 | -24.53% |
| Price to Sales | 17.19 | 8.57 | 8.20 | 6.62 | -62.69% |
| Price to Tangible Book Value | 5.36 | 6.00 | 6.43 | 5.82 | -24.56% |
| Enterprise Value to EBITDA | -111.62 | -122.88 | -370.27 | -145.44 | 32.27% |
| Return on Equity | -15.5% | -20.0% | -29.7% | -22.6% | -20.28% |
| Total Debt | $350.60M | $362.81M | $387.92M | $410.24M | 18.36% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
